Celgene 4Q09 4Q Revenues: $761 million (+21%) 4Q Earnings: $254 million (loss of $154 million in 4Q08) FY Revenues: $2.7 billion (+19%) FY Earnings: $776 million (loss of $1.5 billion in FY08) Comments: Revlimid sales were up 29% to $1.7 billion in FY09, and up 35% to $497 million in 4Q09. Losses in FY08 were largely attributed to the acquisition of Pharmion Corp. in-process R&D write-downs....